On Mar. 2, 2020, Mateon Therapeutics reported the company had been evaluating its therapeutic and AI platforms to aid in the treatment of the current COVID-19 virus outbreak, in response to inquiries about the potential of its technologies.

The new division will be dedicated to the development of rapid responses to the current COVID-19 virus outbreak, as well as future virus outbreaks.